Recruiting NCT07598383
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: VC005 group, VC005 Placebo group.
- Who it may be relevant to
- Registry conditions: Atopic Dermatitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis
Interventions
- Drug VC005 group
VC005 group with Local topical application - Drug VC005 Placebo group
VC005 Placebo group with Local topical application
Primary outcome measures
- Changes in EASI（Eczema area and severity index） from baseline [Time frame: Week 4]
Eligibility criteria
Inclusion criteria
- Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);
- The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;
- During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.
Exclusion criteria
- Patients judged by the investigator to have an unstable course of Atopic Dermatitis (AD) (spontaneous improvement or rapid deterioration) within 2 weeks before baseline;
- Patients with skin lesions limited to the hands or feet at screening and baseline, with no prior history of involvement in other typical areas (such as the face or flexural folds);
- Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., hyperpigmentation, large-area scars, tattoos, etc. at the affected site);
- Presence of skin diseases at screening and baseline that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton's syndrome, etc.;
- Patients with a history of malignant tumors, with the exception of: cervical carcinoma in situ, non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma, or non-metastatic papillary thyroid carcinoma that have been completely resected with no evidence of recurrence for more than 5 years of survival.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Hangzhou First People's Hospital — Hangzhou
Identifiers
NCT: NCT07598383 · VC005-209